Bayer receives UK MHRA approval for Lynkuet to treat moderate to severe vasomotor symptoms associated with menopause: Berlin Saturday, July 12, 2025, 10:00 Hrs [IST] Bayer announc ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Millions of lives and decades of progress hang in the balance,” says the president of the International AIDS Society (IAS) ...

Women in the UK will soon have access to a new daily pill designed to alleviate hot flushes during menopause, following its ...

A treatment for menopausal hot flushes has been approved by medicine watchdogs. UK regulators have become the first in the ...

Women will be able to access a daily pill for hot flushes during menopause after it was given the green light for UK use. The Medicines and Healthcare products Regulatory Agency (MHRA) said it is the ...

Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...